recently stated that they own a 6.8% stake in Teva Pharmaceutical Industries Ltd (NYSE:TEVA) in a Form 13D/A disclosure that was filed with the Securities and Exchange Commission on Friday, January 12th. The investor owns 68,741,067 shares of the stock worth $1,542,549,543. The reporting parties listed on the disclosure included Allergan Holdings B1, Inc, Allergan WC Holding Inc, Warner Chilcott Limited, Allergan WC Holdings Ireland Limited (formerly known as Warner and Allergan plc. The disclosure is available through the SEC website at this hyperlink.
TEVA has been the subject of several recent analyst reports. Goldman Sachs Group upgraded Teva Pharmaceutical Industries from a “neutral” rating to a “buy” rating and set a $20.00 price target for the company in a report on Friday, December 15th. Credit Suisse Group restated an “underperform” rating and issued a $8.00 price target (down previously from $14.00) on shares of Teva Pharmaceutical Industries in a report on Monday, November 6th. Cantor Fitzgerald set a $18.00 price target on Teva Pharmaceutical Industries and gave the company a “hold” rating in a report on Thursday, December 28th. Royal Bank of Canada lowered their price target on Teva Pharmaceutical Industries from $21.00 to $15.00 and set an “underperform” rating for the company in a report on Monday, September 18th. Finally, Wells Fargo & Co restated a “market perform” rating on shares of Teva Pharmaceutical Industries in a report on Thursday, October 5th. Seven research analysts have rated the stock with a sell rating, sixteen have assigned a hold rating, nine have assigned a buy rating and one has given a strong buy rating to the stock. The company currently has a consensus rating of “Hold” and an average price target of $21.17.
Teva Pharmaceutical Industries Ltd (NYSE TEVA) opened at $22.44 on Friday. The company has a market capitalization of $22,090.00, a P/E ratio of -3.82, a P/E/G ratio of 1.36 and a beta of 0.54. The company has a current ratio of 0.96, a quick ratio of 0.66 and a debt-to-equity ratio of 1.20. Teva Pharmaceutical Industries Ltd has a 52-week low of $10.85 and a 52-week high of $37.94.
Teva Pharmaceutical Industries Company Profile
Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.
Want to see what other hedge funds are holding TEVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Teva Pharmaceutical Industries Ltd (NYSE:TEVA).
Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.